Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07279025 · ClinicalTrials.gov registry record
Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety
A clinical trial, sponsored by Deliberate Solutions.
- Not yet
- Registry status
- 150
- Enrollment target
NCT07279025: Clinical Trial study, sponsored by Deliberate Solutions.
NCT07279025 is a clinical trial that has not yet begun recruiting, run by Deliberate Solutions. The registered enrollment target is 150 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07279025 has not yet begun recruiting, sponsored by Deliberate Solutions.
- NOT YET RECRUITING
- Registry status
- 150 participants
- Enrollment target
Study Summary
This study evaluates the reliability and responsiveness of the AI-COA®, a digital tool designed to assess the severity of depression and anxiety. The study compares the tool's performance against standard clinician ratings over 12 weeks to determine its consistency and sensitivity to symptom changes.
Primary Outcome
Concordance of HAM-D score between model and human raters
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-03-01 |
| Est. Completion | 2027-02-28 |
What is known before NCT07279025 opens enrollment
NCT07279025 is an observational study that tracks outcomes without assigning an intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT07279025 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07279025 about?
NCT07279025 is a clinical study titled "Validate the Temporal Stability and Responsiveness of AI-COA® for Depression and Anxiety". This study evaluates the reliability and responsiveness of the AI-COA®, a digital tool designed to assess the severity of depression and anxiety. The study compares the tool's performance against standard clinician ratings over 12 weeks to determine its consistency and sensitivity to symptom changes...
What is the current status of trial NCT07279025?
This trial is currently not yet recruiting. The enrollment target is 150 participants. The study started on 2026-03-01. Estimated completion is 2027-02-28.
Who is sponsoring clinical trial NCT07279025?
This trial is sponsored by Deliberate Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI